Evaluation of Medication Use among Discharged IHD Patients at Private and Public Hospitals in Sana’a city, Yemen.
DOI:
https://doi.org/10.65693/irss.2022.v3i1.417Keywords:
Medication UseAbstract
Isc (IHDs) are a leading cause of death worldwide. Although prescribing according to guidelines improves health outcomes. We determined whether interventions targeted at healthcare professionals are effective to enhance prescribing and health outcomes in patients with Ihemic heart diseasesHDs.
References
1.Fihn SD, Gardin JM, Abrams J, J Am Coll Cardiol. 2012;60(24):e44–e164.
2012 ACCF/AHA/ ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
2.Fihn SD, Blankenship JC, Alexander KP, J Am Coll Cardiol. 2014;64(18):1929 1949. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
3.Levine GN, Bates ER, Bittl JA, J Am Coll Cardiol. 2016;68(10):1082–1115.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
4.Benjamin EJ, Blaha MJ, Chiuve SE, Circulation. 2017;135(10):e146–e603. Heart Disease and Stroke Statistics-2017 Update: a report from the American Heart Association.
5.Alberti KG, Eckel RH, Grundy SM,2009;120(16):1640–1645. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation.
6.Lanza GA, Crea F. 2010;121(21):2317–2325. Primary coronary microvascular dysfunction:
clinical presentation, pathophysiology, and management. Circulation.
7.Stone GW, Maehara A, Lansky AJ, N Engl J Med. 2011;364(3):226–235. A prospective natural- history study of coronary atherosclerosis.
8.Braunwald E, Jones RH, Mark DB,Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation. 1994;90(1):613–622.
9.Sangareddi V, Chockalingam A, Gnanavelu G, Subramaniam T, Jagannathan V, Elangovan S. Canadian Cardiovascular Society classification of effort angina: an angiographic correlation. Coron Artery Dis. 2004;15(2):111–114.
10.Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24(10):946–955.
71
Chapter 6 References
11.Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P.1998;12(3):239–244. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther.
12.Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation.
13.Kuehn BM. 2009;302(8):834. Varenicline gets stronger warnings about psychiatric problems, vehicle crashes. JAMA.
14.Eckel RH, Jakicic JM, Ard JD, et al. 2014;63(25 Pt B):2960–2984. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol.
15. Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G. 2005;25(2):171–183.
Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy.
16.Taylor RS, Brown A, Ebrahim S, et al. 2004;116(10):682–692. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med.
17.Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. 2009;373(9667):911–918. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet.
18.Palmerini T, Benedetto U, Biondi-Zoccai G, et al. 2015;65(23):2496–2507. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol.
19.Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. JAMA Intern Med. 2014;174(2):223–230. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era.
20.Stone NJ, Robinson JG, Lichtenstein AH, et al. 2014;63(25 Pt B): 2889–2934. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol.
21. Whelton PK, Carey RM, Aronow WS, et al. J Am Coll Cardiol. 2017 Nov 13. [Epub ahead of print.]2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
22. alwsaby, M. (2017). The Relationship Between Human Resources Development and the Efficacy of Applying Accreditation Standards in Private and Public Yemeni Hospitals in the Capital City, Sana’a (Z. Murad, Trans.). Institutional Repository for Scientific Scholarship at 21 September University for Medical and Applied Sciences, 1(1), 75-94. https://ojs.21umas.edu.ye/irss/article/view/46
23. Al-wesabi, Muneer. (2012). The Role of Quality Systems in Improving the Performance of Healthcare Facilities in Yemen: A Case Study of the 48 Model Hospital. https://doi.org/10.13140/RG.2.2.12720.32009
24. Al-wesabi, Muneer. (2017). The Effect of Health Human Resources Development on the Efficacy of Applying Accreditation Standards in Yemeni Hospitals: A Field Study. https://doi.org/10.13140/RG.2.2.28658.67527
25. Al-Wesabi, M., & Shamlan, M. (2022). The Effect of Applying Infection Prevention and Control Standards in Sana’a Governorate Hospitals at the Level of Reducing the Spread of Diseases and Epidemics. Journal of September University for Medical and Applied Sciences, 1(1). https://doi.org/10.65693/masj.2022.v1i1.17
26. Alyahawi, A., Al-Wesabi, M., & ALKaf, A. (2022). Antimicrobial susceptibility of Acinetobacter clinical isolates among ICU Patients in Sana’a City, Yemen. Journal of 21 September University for Medical and Applied Sciences, 1(1). https://doi.org/10.65693/masj.2022.v1i1.14
27. Alyahawi, A., & Al-Wesabi, M. (2018). A study of medication use within insured patients with chronic diseases. Institutional Repository for Scientific Scholarship at 21 September University for Medical and Applied Sciences, 1(1), 72273-72281.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 اليحوي، حافظ محمد غياث، شائف عبدالله مرشد، عبدالرحمن محمد، محمد حسين النصيري، محمد عبدالله طلان، معمر محمد صالح، البراء يحيى احمد، بكر محمد عبدالله، صخر محمد العصيمي، حبيب منصور علي، صالح صغير جبوخ، النجار، امين سمير الفقية، اياد احمد الظاهري، احمد حسين الحرورة، اشرف علي الصلاحي، عبدالرحمن احمد دحمل، عبدالمجيد عبدالله الصرابي، محمد احمد الجبرني، ادم ماجد المولد، محمد عبد القوي الشراعي، ضياء الدين عبدالكريم (المؤلف)
This work is licensed under a Creative Commons Attribution 4.0 International License.
